NodThera is planning to initiate a phase 2 proof of concept study in patients in 2022. A second NLRP3 inhibitor, NT-0249, is peripherally restricted and in development to treat chronic ...
The decision follows observations of liver transaminitis without clinically significant symptoms, and without clear dose dependence, in some patients in the azelaprag arms of the STRIDES Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback